Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$4.94 -4.3%	$5.20	$3.79 ▼ $14.60	$257.03M	-0.87	1.46 million shs	791,769 shs
CRDF Cardiff Oncology	$3.70 -4.1%	$3.06	$2.01 ▼ $5.64	$253.46M	1.61	1.17 million shs	1.35 million shs
DBVT DBV Technologies	$9.47 -0.8%	$8.99	$2.20 ▼ $12.78	$249.25M	-0.63	190,181 shs	35,081 shs
SPK SPK Acquisition	$10.30	$10.22	$9.84 ▼ $10.68	$67.94M	-0.01	12,839 shs	33,515 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	-4.26%	-15.56%	-7.66%	-44.49%	-31.58%
CRDF Cardiff Oncology	-4.15%	-13.95%	+31.67%	-3.65%	+38.58%
DBVT DBV Technologies	-0.84%	+5.22%	-14.68%	+98.28%	+89.40%
SPK SPK Acquisition	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CADL Candel Therapeutics	3.0368 of 5 stars	3.5	3.0	0.0	0.0	3.8	1.7	0.6
CRDF Cardiff Oncology	1.6889 of 5 stars	3.5	0.0	0.0	0.0	3.8	0.0	0.6
DBVT DBV Technologies	3.3928 of 5 stars	3.3	5.0	0.0	0.0	3.0	2.5	0.6
SPK SPK Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	3.00	Buy	$21.00	325.10% Upside
CRDF Cardiff Oncology	3.00	Buy	$12.00	224.32% Upside
DBVT DBV Technologies	2.50	Moderate Buy	$14.75	55.76% Upside
SPK SPK Acquisition	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SPK, CADL, CRDF, and DBVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
5/5/2025	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $16.00
5/1/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $15.00
4/11/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	$120K	2,062.45	N/A	N/A	$1.41 per share	3.50
CRDF Cardiff Oncology	$680K	362.00	N/A	N/A	$1.86 per share	1.99
DBVT DBV Technologies	$4.15M	62.50	N/A	N/A	$1.42 per share	6.67
SPK SPK Acquisition	N/A	N/A	N/A	N/A	($0.19) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$55.18M	-$1.34	N/A	N/A	N/A	N/A	-136.74%	-63.13%	8/12/2025 (Estimated)
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
SPK SPK Acquisition	-$420K	N/A	0.00	∞	N/A	N/A	N/A	-1.95%	N/A

Latest SPK, CADL, CRDF, and DBVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million
4/11/2025	Q4 2024	DBVT DBV Technologies	N/A	-$1.10	N/A	-$1.10	N/A	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
SPK SPK Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	N/A	1.18	1.18
CRDF Cardiff Oncology	N/A	4.74	4.74
DBVT DBV Technologies	N/A	2.22	2.22
SPK SPK Acquisition	N/A	4.64	4.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
CRDF Cardiff Oncology	16.29%
DBVT DBV Technologies	71.74%
SPK SPK Acquisition	19.64%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	16.60%
CRDF Cardiff Oncology	7.70%
DBVT DBV Technologies	1.44%
SPK SPK Acquisition	22.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	50.10 million	41.79 million	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
SPK SPK Acquisition	2,021	6.60 million	5.12 million	Not Optionable

SPK, CADL, CRDF, and DBVT Headlines

Recent News About These Companies

ASX 200 telco marches higher on $820 million asset sale

July 11, 2022 | fool.com.au

P&W, Embraer complete first full-SAF test flight with E195-E2

July 2, 2022 | flightglobal.com

Piezoelectric Tiles Market Research Report by Material, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

June 27, 2022 | uk.finance.yahoo.com

SPK Acquisition Corp. Cl A

May 21, 2022 | barrons.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPK, CADL, CRDF, and DBVT Company Descriptions

Candel Therapeutics NASDAQ:CADL

$4.94 -0.22 (-4.26%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$5.01 +0.07 (+1.52%)

As of 06:30 AM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Cardiff Oncology NASDAQ:CRDF

$3.70 -0.16 (-4.15%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$3.36 -0.34 (-9.19%)

As of 05:50 AM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DBV Technologies NASDAQ:DBVT

$9.30 -0.25 (-2.57%)

As of 06/17/2025 04:00 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

SPK Acquisition NASDAQ:SPK

SPK Acquisition Corp. intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on operating businesses in the telecommunications, media, and technology sectors in Asia. The company was incorporated in 2020 and is based in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time